Galapagos NV

NASDAQ: GLPG · Real-Time Price · USD
27.13
-0.21 (-0.77%)
At close: May 05, 2025, 3:59 PM
27.15
0.07%
After-hours: May 05, 2025, 04:43 PM EDT
-0.77%
Bid 24.5
Market Cap 1.79B
Revenue (ttm) 288.19M
Net Income (ttm) -169.54M
EPS (ttm) -0.02
PE Ratio (ttm) -1356.5
Forward PE -19.64
Analyst Hold
Ask 28
Volume 260,238
Avg. Volume (20D) 306,895
Open 27.48
Previous Close 27.34
Day's Range 27.07 - 27.48
52-Week Range 22.36 - 31.23
Beta -0.01

About GLPG

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The compan...

Industry Biotechnology
Sector Healthcare
IPO Date Feb 27, 2012
Employees 704
Stock Exchange NASDAQ
Ticker Symbol GLPG
Full Company Profile

Analyst Forecast

According to 4 analyst ratings, the average rating for GLPG stock is "Hold." The 12-month stock price forecast is $24, which is a decrease of -11.54% from the latest price.

Stock Forecasts
2 months ago
+2.08%
Galapagos shares are trading lower after the compa... Unlock content with Pro Subscription
8 months ago
+9.66%
Galapagos shares are trading higher after Ecor1 Capital reported a 9.9% stake in the company.